EEG as a translational biomarker and outcome measure in fragile X syndrome

Targeted treatments for fragile X syndrome (FXS) have frequently failed to show efficacy in clinical testing, despite success at the preclinical stages. This has highlighted the need for more effective translational outcome measures. EEG differences observed in FXS, including exaggerated N1 ERP ampl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenny, Aisling, Wright, Damien, Stanfield, Andrew C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786970/
https://www.ncbi.nlm.nih.gov/pubmed/35075104
http://dx.doi.org/10.1038/s41398-022-01796-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786970/
https://www.ncbi.nlm.nih.gov/pubmed/35075104
http://dx.doi.org/10.1038/s41398-022-01796-2

Ejemplares similares